Company News: Page (1) of 1 - 01/10/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

Uptick Newswire “Stock Day” Interviews CEO of SANUWAVE Health on the 2018 Expansion and the Newly U.S. Marketed dermaPACE System

(January 10, 2018)

PHOENIX, Jan. 10, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire is the sole producer of the Uptick Network’s “Stock Day” Podcast, updating investors and shareholders on the micro-cap sector of the market. Since the inception of “Stock Day” in January 2016 CEO and host Everett Jolly has interviewed over 600 CEO’s within the micro-cap publicly traded sector of the market, bringing transparency and a connection to the investor community.

Recently on “Stock Day” Everett Jolly welcomed back this astonishing Company with a stock price overview; “I tell you what this company is crushing it! Like I said last time this Company was on they were trading around .14 cents and now they are trading at .25 cents.” Kevin Richardson, CEO of SANUWAVE Health, Inc. (OTCQB:SNWV) (“Sanuwave” or the “Company”) started off the interview with an overview of the Company’s latest Class II medical device the dermaPACE System.  Using Pulsed Acoustic Cellular Expression (PACE) Technology Sanuwave plans to intersect the $4 billion advanced wound care market.  With diabetes on the rise there is a growing need for such wound care technology.

Noting the Company’s successes of 2017 Mr. Jolly asks if the Company “Has any goals or milestones you want to measure for your success in 2018?”

With that question on the table Mr. Richardson states, “As we look at 2018, especially with the US approval to market the dermaPACE, I hope to see us at least double revenue in 2018 which is one of our goals. You’re going to see us announce, hopefully, one or more of a Brazil type deal with a different country or region of the world similar to the size of Brazil. We anticipate launching some new studies helping us support the growth of the diabetic foot ulcer business in the U.S. and you’ll see us bring on some new employees as needed to help support the growth within the Company.”

Richardson concludes the interview with confidence with the aggressive expansion plans of their latest technology into the U.S. and the results it should produce for the investors.

Listen to the full interview by clicking here or the following link: https://upticknewswire.com/featured-interview-ceo-kevin-richardson-of-sanuwave-health-inc-otcqb-snwv

About Uptick Newswire and the “Stock Day Podcast”

Uptick Newswire is a private company reaching out to the masses keeping investors and shareholders up to date on company news and bringing transparency to the undervalued, undersold, micro-cap stocks of the market and is the sole producer of the Uptick Network “Stock Day” Podcast. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire and has recently launched the Video Interview Studio located in Phoenix, Arizona with its new host, Kathryn Donnelly. 


https://www.youtube.com/watch?v=kU5SVLp4org

Follow us and keep an eye on Uptick's YouTubeTwitter, and Facebook for additional radio and video shows produced by Uptick! https://upticknewswire.com/

Investors Hangout is a proud sponsor of “Stock Day.”  Uptick Newswire encourages listeners to visit SANWAVE Health’s message board on: https://investorshangout.com/Sanuwave-Health-Inc-SNWV-66973/

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE System has been approved under the FDA’s de novo petition process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.

Contact:
Uptick Newswire LLC
Everett Jolly, CEO/Founder
602-441-3474
10000 N. 31st Avenue C307
Phoenix, AZ 85051
[email protected]
www.upticknewswire.com

Source: Uptick Newswire


Page: 1


Related Keywords:

-->

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved